Humasis Co

Humasis Co FCF per Share

The Free Cash Flow per Share of Humasis Co (205470.KQ) as of Nov 11, 2026 is 304.46 KRW. In the previous year, Free Cash Flow per Share was 909.75 KRW — a change of -66.53% (lower).

FCF per Share

304.46KRW

YoY

-66.53%

Last updated:

Free Cash Flow per Share of Humasis Co is 2025 304.46 KRW. Free Cash Flow per Share of Humasis Co was 2024 909.75 KRW. It decreases by -66.53% lower compared to the previous year.

The Humasis Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-54.53 KRW
Jan 1, 2019
-69.28 KRW
Jan 1, 2020
-24.58 KRW
Jan 1, 2021
5,866.27 KRW
Jan 1, 2022
4,957.75 KRW
Jan 1, 2023
-2,473.09 KRW
Jan 1, 2024
909.75 KRW
Jan 1, 2025
304.46 KRW
The Humasis Co FCF per Share history
YEARFCF per ShareYoY
304.46KRW-66.53%
909.75KRW-136.79%
-2,473.09KRW-149.88%
4,957.75KRW-15.49%
5,866.27KRW-23,965.38%
-24.58KRW-64.52%
-69.28KRW+27.06%
-54.53KRW-58.77%
-132.26KRW-2,888.84%
4.74KRW-5.80%
5.03KRW-319.95%
-2.29KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Free Cash Flow per Share of Humasis Co is 304.46 KRW in 2025.

Free Cash Flow per Share of Humasis Co changed from 909.75 KRW to 304.46 KRW, representing a -66.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Humasis Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Humasis Co

All Key Metrics — Humasis Co